@article{fdi:010093129,
  title = {{G}rowth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir {HIV} prophylaxis in early life},
  author = {{N}agot, {N}. and {S}ingata-{M}adliki, {M}. and {C}ournil, {A}mandine and {N}alugya, {J}. and {T}assembedo, {S}. and {Q}uillet, {C}. and {T}onga, {M}.{W}. and {T}umwine, {J}. and {M}eda, {N}. and {K}ankasa, {C}. and {M}wiya, {M}. and {B}angirana, {P}. and {P}eries, {M}. and {B}atting, {J}. and {E}ngebretsen, {I}.{M}.{S}. and {T}ylleskär, {T}. and {V}ande {P}erre, {P}. and {N}deezi, {G}. and {M}ol{\`e}s, {J}.{P}.},
  editor = {},
  language = {{ENG}},
  abstract = {{I}n the {ANRS} 12174 trial, {HIV}-exposed uninfected {A}frican neonates who received lopinavir-ritonavir ({LPV}/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3{TC}). {W}e assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. {B}etween {F}ebruary 2017 and {F}ebruary 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not {HIV}-infected. {I}n addition to clinical examination, neuropsychological outcomes were assessed using the tests {K}aufman-{ABCII}, {T}est of {V}ariables of {A}ttention, {M}ovement {A}ssessment {B}attery for {C}hildren and the {S}trengths and {D}ifficulties questionnaire, parent version. {O}f 1101 eligible children, aged 5-7 years, 553 could be traced and analysed (274 in the {LPV}/r and 279 in the 3{TC} groups). {G}rowth, clinical and neuropsychological outcomes did not differ between treatment groups. {A}t school age, children exposed to {LPV}/r and 3{TC} at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of {LPV}/r. {I}t provides reassuring data on clinical outcomes for all {HIV}-infected children treated with this antiretroviral drug in early life.},
  keywords = {{BURKINA} {FASO} ; {AFRIQUE} {DU} {SUD} ; {OUGANDA} ; {ZAMBIE}},
  booktitle = {},
  journal = {{S}cientific {R}eports},
  volume = {11},
  numero = {1},
  pages = {3173 [10 ]},
  ISSN = {2045-2322},
  year = {2021},
  DOI = {10.1038/s41598-021-82762-8},
  URL = {https://www.documentation.ird.fr/hor/fdi:010093129},
}